Industry News

Biotechnology Industry News

Neuro-focused Encoded Therapeutics…

September 9th, 2026|FierceBiotech|

Neuro-focused Encoded Therapeutics has bagged a $275 million series F round to support its Dravet syndrome asset and scale up its internal manufacturing capabilities.

Tyra Biosciences has reported…

September 9th, 2026|FierceBiotech|

Tyra Biosciences has reported initial phase 2 data on dabogratinib in bladder cancer, putting the biotech on course to start a registrational study next year. But the biotech’s stock fell in premarket trading after the

A phase 2 trial of Beeline…

September 9th, 2026|FierceBiotech|

A phase 2 trial of Beeline Medicines’ afimetoran has hit its primary endpoint, positioning the biotech to swarm into pivotal development in two forms of lupus.

Evommune’s MRGPRX2 antagonist…

September 9th, 2026|FierceBiotech|

Evommune’s MRGPRX2 antagonist has flunked another phase 2 trial, wiping out the biotech’s last hopes of developing the therapy for any itch-related conditions.

Solstice Oncology has secured $225…

September 9th, 2026|FierceBiotech|

Solstice Oncology has secured $225 million in series A funds to advance a next-gen immunotherapy that the biotech hopes will turn “darkness to light” for cancer care.

With a detailed data drop that…

September 8th, 2026|FierceBiotech|

With a detailed data drop that AstraZeneca’s R&D chief describes as an internal “science success story,” the British Big Pharma has secured an FDA priority review for what it believes could become a flagship biologic

Pharvaris’ deucrictibant has…

September 8th, 2026|FierceBiotech|

Pharvaris’ deucrictibant has tasted success in a second phase 3 study, strengthening the case for the therapy to treat hereditary angioedema patients as the Swiss biotech awaits an FDA approval decision.

A pivotal trial of Bristol Myers…

September 8th, 2026|FierceBiotech|

A pivotal trial of Bristol Myers Squibb’s GPRC5D-directed CAR-T cell therapy has hit its primary endpoint, furthering the drugmaker’s efforts to challenge Johnson & Johnson for the post-BCMA multiple myeloma market.

The phase 3 Harbor trial of…

September 8th, 2026|FierceBiotech|

The phase 3 Harbor trial of Novartis’ del-desiran has missed its primary endpoint, dealing a major blow to an asset that the Swiss drugmaker acquired in the $12 billion takeover of Avidity Biosciences. The flop

Inhibrx Biosciences’ CEO has…

September 8th, 2026|FierceBiotech|

Inhibrx Biosciences’ CEO has argued that the 9.6 months of progression-free survival demonstrated by its OX40 agonist in a phase 2 study has proven the therapy’s durability in treating head and neck cancer.

A startup spawned from Seattle…

September 7th, 2026|FierceBiotech|

A startup spawned from Seattle Children’s Hospital has raised a $116 million series A to advance cell therapies for devastating childhood brain tumors.

Novo Nordisk has given up on two…

September 7th, 2026|FierceBiotech|

Novo Nordisk has given up on two more phase 3 trials of ziltivekimab, further eroding the prospects for a molecule that analysts had once tipped as a potential blockbuster.

ADARx has reinvigorated its…

September 6th, 2026|FierceBiotech|

ADARx has reinvigorated its ambitions to go public as the AbbVie-backed biotech looks to fund ongoing clinical trials of a range of next-gen small interfering RNA medicines.

Novartis’ Ionis-partnered drug…

September 4th, 2026|FierceBiotech|

Novartis’ Ionis-partnered drug designed to lower levels of Lp(a), a known cardiovascular risk factor, failed to reduce patients’ risk of a heart attack, stroke, or other major cardiovascular event in the first late-stage test for

Italian company the Menarini Group…

September 4th, 2026|FierceBiotech|

Italian company the Menarini Group has agreed to pay Chinese insulin maker Gan & Lee Pharmaceuticals €62 million ($72 million) up front to collaborate on the registration and commercialization of Gan & Lee’s GLP-1 bofanglutide.